pharma
Bial - Portela
Bial - Portela Cª
Bial - Portela patent portfolio — 21 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- TROFA, PT
- Programs
- 0
- Drugs
- 0
- Patents
- 21
Bial - Portela patents
21 pharmaceutical patents indexed for Bial - Portela. 0 expire within 24 months.
Bial - Portela has 21 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
WO 2022081033
OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
granted -
WO 2022025781
DISPERSION SOLIDE D'OPICAPONE
granted -
WO 2021182981
OPICAPONE MICRONISÉE
granted -
WO 2020246903
INHIBITEURS DE DOPAMINE-B-HYDROXYLASE
granted -
AU 2018379646
Dopamine-B-hydroxylase inhibitors
granted -
BR PI0923819
compostos farmacêuticos
granted -
EP 3515433
DIE BLUT-HIRN-SCHRANKE PASSIERENDE DOPAMIN-B-HYDROXYLASE-INHIBITOREN
granted -
US 2019008774
PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME
granted -
PT 2114927
PROCESS FOR THE PREPARATION OF (R)-5-(2-AMINOETHYL)-1-(6,8-DIFLUOROCHROMAN-3-YL)-1,3-DIHYDROIMIDAZOLE-2-THIONE
granted -
PT 2121138
THERAPEUTICAL USES OF ESLICARBAZEPINE
granted -
PT 2214636
ORAL DOSAGE FORMS COMPRISING LICARBAZEPINE ACETATE
granted -
PT 2481410
NITROCATECHOL DERIVATES AS COMT INHIBITORS ADMINISTERED WITH A SPECIFIC DOSAGE REGIME
granted -
US 2015359783
PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THEREOF
granted -
PT 2303855
CATALYTIC PROCESS FOR ASYMMETRIC HYDROGENATION
granted -
WO 2015016729
COMPOSÉS D'URÉE ET LEUR UTILISATION COMME INHIBITEURS DE L'ENZYME FAAH
granted -
WO 2015016728
COMPOSÉS D'URÉE ET LEUR UTILISATION COMME INHIBITEURS DE L'ENZYME FAAH
granted -
EP 2791134
CHEMISCHE VERBINDUNG ALS ZWISCHENPRODUKT ZUR HERSTELLUNG EINES CATECHOL-O-METHYLTRANSFERASE-INHIBITORS
granted -
WO 2014163518
TRAITEMENTS UTILISANT L'ESLICARBAZÉPINE ET L'ACÉTATE D'ESLICARBAZÉPINE
granted -
EP 2747770
BEHANDLUNGEN MIT ESLICARBAZEPINACETAT ODER ESLICARBAZEPIN
granted -
CA 2890920
DERIVES DE 1,3-DIHYDROIMIDAZOLE-2-THIONE UTILISABLES DANS LE TRAITEMENT DE L'HYPERTENSION ARTERIELLE PULMONAIRE ET DES LESIONS PULMONAIRES
granted -
MX 2013007491
GRANULATES COMPRISING ESLICARBAZEPINE ACETATE.
granted
Frequently asked questions
How many patents does Bial - Portela have?
21 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Bial - Portela patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.